Previous 10 | Next 10 |
LA JOLLA, Calif. , Jan. 7, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as a clinical candidate for the t...
Nano cap Regulus Therapeutics (NASDAQ: RGLS ) is up 8% after hours in response to its announcement of positive results from a new mouse toxicity study of RGLS4326, a candidate for autosomal dominant polycystic kidney disease (ADPKD). More news on: Regulus Therapeutics, Health...
LA JOLLA, Calif. , Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a planned interim data analysis fro...
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...
ConvergeOne Holdings (NASDAQ: CVON ) +32% on being acquired by CVC Fund. More news on: ConvergeOne Holdings, Inc., Vericel Corporation, e.l.f. Beauty, , Stocks on the move, Top stock market news, Read more ...
Nano cap Regulus Therapeutics (NASDAQ: RGLS ) is up 20% premarket on increased volume on the heels of its restructured collaboration agreement with Sanofi (NYSE: SNY ) featuring the out-licensing of global exclusive rights to develop and commercialize RG-012 for all indications...
LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and Lic...
LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from ATHENA, its global natural history ...
Gainers: RGLS +55% . PLAG +46% . CASI +42% . TRPX +26% . CORV +19% . EVK +18% . HMNY +16% . AUDC +15% . SENS +15% . CCCL +13% . More news on: Regulus Therapeutics, Planet Green Holdings Corp, CASI Pharmaceuticals, Stocks on the move, , Top stock market...
CORAL GABLES, FL / ACCESSWIRE / October 23, 2018 / The stock market turned bearish during the early morning hours. International concern drove futures lower before the opening bell on Tuesday. Many investors have begun flocking to safe haven stocks for more protection to their portfolios. ...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...